Dr Reddys Laboratories Limited logo

Dr Reddys Laboratories LimitedNYSE: RDY

Profile

Sector:

Healthcare

Country:

India

IPO:

11 April 2001

Next earnings report:

05 November 2024

Last dividends:

30 July 2024

Next dividends:

N/A
$2.47 B
-12%vs. 3y high
83%vs. sector
-50%vs. 3y high
7%vs. sector
-20%vs. 3y high
34%vs. sector
-12%vs. 3y high
19%vs. sector

Price

regular market | Mon, 04 Nov 2024 14:30:00 GMT
$14.80-$59.20(-80.00%)
$919.71 M$909.16 M
$919.71 M$166.86 M

Analysts recommendations

Institutional Ownership

RDY Latest News

Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
businesswire.com02 October 2024 Sentiment: POSITIVE

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.

Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
zacks.com21 August 2024 Sentiment: POSITIVE

Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.

Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
seekingalpha.com13 August 2024 Sentiment: POSITIVE

Dr. Reddy's Laboratories stock has risen 29% since my last publication, with additional tailwinds from legislative changes and strong business momentum. The company's enduring competitive advantage as a generics pharmaceutical manufacturer produces abnormally high and persistent returns on capital. Quarterly insights show growth in U.S. generics, Europe, and India markets, with high-quality economic characteristics supporting $107/share intrinsic value.

Dr. Reddy's Laboratories: India 'will be our number one market'
youtube.com30 July 2024 Sentiment: POSITIVE

Erez Israeli of Dr. Reddy's Laboratories says the company is "absolutely planning to play" in the biologics space, and while the U.S. remains a key market for the company, India and other markets will grow faster.

Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
zacks.com29 July 2024 Sentiment: POSITIVE

Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India.

Dr. Reddy's Q1FY25 Financial Results
businesswire.com27 July 2024 Sentiment: NEUTRAL

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2024.

Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
zacks.com27 June 2024 Sentiment: POSITIVE

Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
businesswire.com28 May 2024 Sentiment: NEUTRAL

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CEO--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.

Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
zacks.com22 May 2024 Sentiment: POSITIVE

Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Zacks Investment Research18 April 2024 Sentiment: POSITIVE

The Zacks Medical - Generic Drugs industry is starting to see some relief from macroeconomic challenges, with new product releases benefiting companies like RDY, TEVA, and VTRS.

  • 1(current)
  • 2

What type of business is Dr Reddys Laboratories Limited?

Dr. Reddy's Laboratories Limited is a global pharmaceutical company founded in 1984, headquartered in Hyderabad, India. The main activities of the company include manufacturing generic and patented drugs for use in various medical fields such as neurology, dermatology, gastroenterology, and oncology. The product portfolio also includes pain relievers and vaccines. In Russia, the following pharmaceutical brands are known: Nise, Omez, Nazivin, Ibuklin. Another business direction of Dr. Reddy's is the production and sale of active pharmaceutical ingredients and their intermediates (API), used in the manufacture of medicinal products.

What sector is Dr Reddys Laboratories Limited in?

Dr Reddys Laboratories Limited is in the Healthcare sector

What industry is Dr Reddys Laboratories Limited in?

Dr Reddys Laboratories Limited is in the Drug Manufacturers - Specialty & Generic industry

What country is Dr Reddys Laboratories Limited from?

Dr Reddys Laboratories Limited is headquartered in India

When did Dr Reddys Laboratories Limited go public?

Dr Reddys Laboratories Limited initial public offering (IPO) was on 11 April 2001

What is Dr Reddys Laboratories Limited website?

https://www.drreddys.com

Is Dr Reddys Laboratories Limited in the S&P 500?

No, Dr Reddys Laboratories Limited is not included in the S&P 500 index

Is Dr Reddys Laboratories Limited in the NASDAQ 100?

No, Dr Reddys Laboratories Limited is not included in the NASDAQ 100 index

Is Dr Reddys Laboratories Limited in the Dow Jones?

No, Dr Reddys Laboratories Limited is not included in the Dow Jones index

When was Dr Reddys Laboratories Limited the previous earnings report?

No data

When does Dr Reddys Laboratories Limited earnings report?

The next expected earnings date for Dr Reddys Laboratories Limited is 05 November 2024